Raushan Kumar Chaudhary
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Raushan Kumar Chaudhary has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Uday Venkat Mateti
Department of Pharmacy Practice, NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Nitte (Deemed to be University), Mangalore, Karnataka, India
10 shared publications - Ramesh Bhandari
Department of Pharmacy Practice, KLE College of Pharmacy Belagavi, KLE Academy of Higher Education and Research (KAHER), Nehru Nagar, 590010, Belagavi, India.
4 shared publications Prakash Patil
Central Research Laboratory (CRL), KS Hegde Medical Academy (KSHEMA), Nitte (Deemed to be University)
3 shared publications- Pukar Khanal
Department of Pharmacology and Chemical Biology, School of Medicine, Emory University, Atlanta, GA, United States
3 shared publications Rajesh Raju
Centre for Systems Biology and Molecular Medicine (CSBMM), Yenepoya Research Centre, Yenepoya (Deemed to be University), Mangalore, 575018, Karnataka, India
3 shared publications- Satish S. Karoli
Department of Pharmacy Practice, KLE College of Pharmacy (A Constituent Unit of KLE Academy of Higher Education and Research)
3 shared publications
Latest Publications
- 25 September 2026
- Published by Bentham Science Publishers Ltd. in Current Drug Safety
- Vol. 21, 1-11
Duality of Rarity of Chemotherapy-induced Flagellate Erythema among Cancer Patients: A Case Report with 26 Years of Evidence in Oncology
Introduction: Flagellate Dermatitis (FD) due to anticancer therapy is a rare, unusual Adverse Drug Reaction (ADR) in oncology. The current case describes the impact of financial constraints on the choice of anticancer therapy, the occurrence of FD and poor outcomes among Hodgkin's Lymphoma patients, and 26 years of evidence on FD due to anticancer therapy. Case Report: A 25-year-old male presented with fever, cough, night sweats, weight loss, and swelling on the right side of the neck, which was diagnosed as Hodgkin's Lymphoma with a complex diagnostic work-up (PET-CT scan, histopathology/immunohistochemistry reports). The patient was planned for Nivolumab-AVD therapy, but treated with ABVD chemotherapy due to financial constraints. Unfortunately, the patient developed linear streaks on the trunk region of the body after 4 days of 1st dose of ABVD therapy, which was diagnosed as FD triggered by Bleomycin. Thus, Bleomycin was omitted from the polychemotherapy regimen (AVD), and ADR was managed with corticosteroids. Although the PET-CT report initially showed a partial response to ABVD/AVD. Later, the disease was found to be metabolically progressive, for which salvage therapy (GDP, DHAP, and palliative radiotherapy) was given. Further, the patient was suggested Brentuximab and Nivolumab therapy, but the patient declined therapy due to financial constraints, lack of funding, and coverage by the government healthcare scheme. Thus, the patient was discharged against medical advice. Conclusion: Healthcare professionals should be aware of and vigilant for this whip-like dermatological manifestation (FD) when choosing Bleomycin-based therapy. A patient-centric approach to cessation or rechallenge with the culprit drug, along with antihistamines and topical/ oral corticosteroids, is the mainstay for the management of FD.
- 25 September 2026
- Published by Bentham Science Publishers Ltd. in Current Drug Safety
- Vol. 21, 1-11
Duality of Rarity of Chemotherapy-induced Flagellate Erythema among Cancer Patients: A Case Report with 26 Years of Evidence in Oncology
Introduction: Flagellate Dermatitis (FD) due to anticancer therapy is a rare, unusual Adverse Drug Reaction (ADR) in oncology. The current case describes the impact of financial constraints on the choice of anticancer therapy, the occurrence of FD and poor outcomes among Hodgkin's Lymphoma patients, and 26 years of evidence on FD due to anticancer therapy. Case Report: A 25-year-old male presented with fever, cough, night sweats, weight loss, and swelling on the right side of the neck, which was diagnosed as Hodgkin's Lymphoma with a complex diagnostic work-up (PET-CT scan, histopathology/immunohistochemistry reports). The patient was planned for Nivolumab-AVD therapy, but treated with ABVD chemotherapy due to financial constraints. Unfortunately, the patient developed linear streaks on the trunk region of the body after 4 days of 1st dose of ABVD therapy, which was diagnosed as FD triggered by Bleomycin. Thus, Bleomycin was omitted from the polychemotherapy regimen (AVD), and ADR was managed with corticosteroids. Although the PET-CT report initially showed a partial response to ABVD/AVD. Later, the disease was found to be metabolically progressive, for which salvage therapy (GDP, DHAP, and palliative radiotherapy) was given. Further, the patient was suggested Brentuximab and Nivolumab therapy, but the patient declined therapy due to financial constraints, lack of funding, and coverage by the government healthcare scheme. Thus, the patient was discharged against medical advice. Conclusion: Healthcare professionals should be aware of and vigilant for this whip-like dermatological manifestation (FD) when choosing Bleomycin-based therapy. A patient-centric approach to cessation or rechallenge with the culprit drug, along with antihistamines and topical/ oral corticosteroids, is the mainstay for the management of FD.
- Open Access
- 31 August 2026
- Published by Springer Nature in Discover Oncology
Repurposing FDA-approved drugs targeting signature genes associated with cancer of unknown primary: an orphanoinformatics approach
Background: Cancer of unknown primary (CUP) is a rare and aggressive metastatic cancer characterized by an undefined primary site of tumor origin with poor overall survival (favorable group: 10–16 months and unfavorable group: 6–7 months). Thus, the current study aimed to identify and repurpose a drug targeting the signature gene involved in CUP pathogenesis. Methods: The relevant dataset for CUP was identified from the GEO database using a systematic search. Oncogene and tumor suppressor genes in CUP were used to identify protein-protein interactions and perform enrichment analysis in STRING. The hub and signature genes involved in CUP were identified using the CytoHubba plugin of Cytoscape 3.10.4. The drug candidates for signature genes were retrieved from GeneCards ® and DGIdb database which were docked to repurpose FDA-approved drugs against the signature target involved in CUP. Results: Out of 4815 genes expressed in CUP, 2670 were upregulated, and 913 were downregulated, of which 144 were oncogenes, and 80 were tumor suppressor genes, respectively. 1039 Gene Ontology terms and 141 KEGG pathways were significantly enriched in the protein-protein interaction network. A total of 43 genes were identified as hub genes involved in CUP, of which 9 ( STAT3/KRAS/NRAS/CTNNB1/TGFB1/JUN/FOS/ERBB2/BCL2 ) were considered signature genes. Dactinomycin, along with Sacituzumab-govitecan, Venetoclax, Dabrafenib, and Sorafenib, showed the highest binding affinity with signature genes. Conclusion: Dactinomycin emerged as the most promising candidate, targeting multiple signature genes (TGFB1, BCL2, STAT3, JUN, and FOS) involved in CUP pathogenesis and exhibiting the highest binding affinity.
- 31 August 2026
- Published by Springer Nature in Discover Oncology
Open AccessRepurposing FDA-approved drugs targeting signature genes associated with cancer of unknown primary: an orphanoinformatics approach
Background: Cancer of unknown primary (CUP) is a rare and aggressive metastatic cancer characterized by an undefined primary site of tumor origin with poor overall survival (favorable group: 10–16 months and unfavorable group: 6–7 months). Thus, the current study aimed to identify and repurpose a drug targeting the signature gene involved in CUP pathogenesis. Methods: The relevant dataset for CUP was identified from the GEO database using a systematic search. Oncogene and tumor suppressor genes in CUP were used to identify protein-protein interactions and perform enrichment analysis in STRING. The hub and signature genes involved in CUP were identified using the CytoHubba plugin of Cytoscape 3.10.4. The drug candidates for signature genes were retrieved from GeneCards ® and DGIdb database which were docked to repurpose FDA-approved drugs against the signature target involved in CUP. Results: Out of 4815 genes expressed in CUP, 2670 were upregulated, and 913 were downregulated, of which 144 were oncogenes, and 80 were tumor suppressor genes, respectively. 1039 Gene Ontology terms and 141 KEGG pathways were significantly enriched in the protein-protein interaction network. A total of 43 genes were identified as hub genes involved in CUP, of which 9 ( STAT3/KRAS/NRAS/CTNNB1/TGFB1/JUN/FOS/ERBB2/BCL2 ) were considered signature genes. Dactinomycin, along with Sacituzumab-govitecan, Venetoclax, Dabrafenib, and Sorafenib, showed the highest binding affinity with signature genes. Conclusion: Dactinomycin emerged as the most promising candidate, targeting multiple signature genes (TGFB1, BCL2, STAT3, JUN, and FOS) involved in CUP pathogenesis and exhibiting the highest binding affinity.
- 11 February 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 32 (7) , 1380-1390
Evaluation of antitumor response to HDAC inhibitors in advanced head and neck cancer: A proportional meta-analysis of clinical trials
Objective: To study the cumulative proportion of favorable response to Histone Deacetylase Inhibitor (HDACi) among head and neck cancer (HNC) patients. Data Sources: A systematic search (till 17 th -May-2025) was carried out in PubMed, Scopus, and Web of Science databases using “Head and Neck cancer” and “HDAC inhibitors” as key concept where all the single-arm clinical trials which have clear data on response to HDACi therapy-based RECIST criteria among HNC patients were included in this study. The meta-analysis was performed using R software. Data Summary: The search resulted in a total of 178 articles, of which 7 studies were found to be relevant based on the inclusion criteria. Out of a total of 101 advanced HNC patients treated with HDACi in single-arm clinical trials, 74 patients showed favorable antitumor response. The pooled cumulative proportion of favorable response with the random effect model was found to be 0.65. Out of these 7 studies, the average proportion of antitumor response was calculated to be 0.758 among HNC patients who received HDACi concurrently with chemotherapy, chemoradiotherapy, and targeted therapy, whereas the average proportion of antitumor response rate to HDACi was 0.485 among priorly treated HNC patients. Vorinostat was the most used HDACi, where the proportion of favorable response was 0.49 compared to the non-vorinostat HDACi (0.77), like valproic acid, panobinostat, and romidepsin. Conclusion: The overall antitumor response to HDACi was found to be 0.65 (65%), which supports the use of HDACi among advanced HNC patients, particularly along with the concurrent chemo/chemoradiotherapy or targeted therapy.
- 11 February 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 32 (7) , 1380-1390
Evaluation of antitumor response to HDAC inhibitors in advanced head and neck cancer: A proportional meta-analysis of clinical trials
Objective: To study the cumulative proportion of favorable response to Histone Deacetylase Inhibitor (HDACi) among head and neck cancer (HNC) patients. Data Sources: A systematic search (till 17 th -May-2025) was carried out in PubMed, Scopus, and Web of Science databases using “Head and Neck cancer” and “HDAC inhibitors” as key concept where all the single-arm clinical trials which have clear data on response to HDACi therapy-based RECIST criteria among HNC patients were included in this study. The meta-analysis was performed using R software. Data Summary: The search resulted in a total of 178 articles, of which 7 studies were found to be relevant based on the inclusion criteria. Out of a total of 101 advanced HNC patients treated with HDACi in single-arm clinical trials, 74 patients showed favorable antitumor response. The pooled cumulative proportion of favorable response with the random effect model was found to be 0.65. Out of these 7 studies, the average proportion of antitumor response was calculated to be 0.758 among HNC patients who received HDACi concurrently with chemotherapy, chemoradiotherapy, and targeted therapy, whereas the average proportion of antitumor response rate to HDACi was 0.485 among priorly treated HNC patients. Vorinostat was the most used HDACi, where the proportion of favorable response was 0.49 compared to the non-vorinostat HDACi (0.77), like valproic acid, panobinostat, and romidepsin. Conclusion: The overall antitumor response to HDACi was found to be 0.65 (65%), which supports the use of HDACi among advanced HNC patients, particularly along with the concurrent chemo/chemoradiotherapy or targeted therapy.
- 18 August 2025
- Published by Taylor & Francis in Biomarkers
- Vol. 30 (6) , 407-419
Unveiling the oncogenic role and prognostic value of ACTL6A in cancer: a systematic review and meta-analysis
Actin-like protein 6A (ACTL6A), a subunit of SWI/SNF (SWItch/Sucrose Non-Fermentable) complex has emerged as a key player in cancer progression. Despite growing evidence of its oncogenic potential, a comprehensive evaluation of its role in tumorigenesis and clinical outcomes remains warranted. This systematic review and meta-analysis aim to elucidate the role of ACTL6A in cancer pathophysiology and its prognostic significance. A systematic search in PubMed, Scopus, and Web of Science was conducted from inception to 31st December 2024, using the keywords "ACTL6A" and "Cancer." Studies investigating ACTL6A's role in cancer and those reporting hazard ratios for ACTL6A expression in human samples were considered for systematic review and meta-analysis, respectively. A total of 39 studies were included in systematic review which collectively reported the role of ACTL6A in tumorigenesis, invasion, and metastasis via HIPPO-YAP, PI3K/AKT, NOTCH and Wnt/β-catenin pathways. Six studies (n = 863) qualified for meta-analysis, revealing that ACTL6A overexpression was significantly associated with poor overall survival (OS) (p = 0.001), larger tumor size (p < 0.01) and higher tumor grade (p = 0.002). ACTL6A is a critical oncogenic driver which promotes cancer progression and poor clinical outcomes. ACTL6A may serve as a promising prognostic marker, paving the way for targeted therapeutic strategies in oncology.
- 18 August 2025
- Published by Taylor & Francis in Biomarkers
- Vol. 30 (6) , 407-419
Unveiling the oncogenic role and prognostic value of ACTL6A in cancer: a systematic review and meta-analysis
Actin-like protein 6A (ACTL6A), a subunit of SWI/SNF (SWItch/Sucrose Non-Fermentable) complex has emerged as a key player in cancer progression. Despite growing evidence of its oncogenic potential, a comprehensive evaluation of its role in tumorigenesis and clinical outcomes remains warranted. This systematic review and meta-analysis aim to elucidate the role of ACTL6A in cancer pathophysiology and its prognostic significance. A systematic search in PubMed, Scopus, and Web of Science was conducted from inception to 31st December 2024, using the keywords "ACTL6A" and "Cancer." Studies investigating ACTL6A's role in cancer and those reporting hazard ratios for ACTL6A expression in human samples were considered for systematic review and meta-analysis, respectively. A total of 39 studies were included in systematic review which collectively reported the role of ACTL6A in tumorigenesis, invasion, and metastasis via HIPPO-YAP, PI3K/AKT, NOTCH and Wnt/β-catenin pathways. Six studies (n = 863) qualified for meta-analysis, revealing that ACTL6A overexpression was significantly associated with poor overall survival (OS) (p = 0.001), larger tumor size (p < 0.01) and higher tumor grade (p = 0.002). ACTL6A is a critical oncogenic driver which promotes cancer progression and poor clinical outcomes. ACTL6A may serve as a promising prognostic marker, paving the way for targeted therapeutic strategies in oncology.
- 1 December 2024
- Published by Bentham Science Publishers Ltd. in Current Pharmacogenomics and Personalized Medicine
- Vol. 21 (3) , 155-164
Understanding Bacterial Roles in Cancer Chemo-resistance: A Signaling Pathway Mapping Study
Introduction: Chemoresistance is one of the leading causes of chemotherapy failure among cancer patients. Out of several hypotheses proposed for chemoresistance, bacteria-mediated chemoresistance to cancer drugs has not been well established. Thus, the aim of this review is to map the pathways by which bacteria exhibit chemoresistance in specific cancers. Material and Methods: Relevant articles on bacteria-mediated chemoresistance in cancer were retrieved by conducting a systematic search across PubMed, Scopus and Web of Science databases. The search was limited to English original articles published until 15th December 2023. Results: A total of nine articles were included to map the pathways involved in chemoresistance. Numerous pathways have been connected to various forms of cancer, such as autophagy pathway in colorectal and esophageal cancers by Fusobacterium nucleatum causing oxaliplatin and 5-FU resistance; DNA damage response pathway also by Fusobacterium nucleatum promoting CDDP resistance in esophageal cancer; Porphyromonas gingivalis led to oral and esophageal cancer resistance to paclitaxel via JAK/STAT pathway. NF-κB pathway involved in gastric cancer in the presence of Helicobacter pylori towards cisplatin, and also 5-FU resistance via the apoptotic pathway. Cellular metabolism modulation by Lactobacillus iners was also implicated in cervical cancer chemoresistance. Conclusion: We conclude that bacteria can mediate chemoresistance not merely to antibiotics but also to anticancer drugs. Thus, a detailed understanding of the pathways associated with chemoresistance mediated via bacteria might help in targeting these pathways or antibiotics to prevent bacterial growth could help overcome resistance.
- 1 December 2024
- Published by Bentham Science Publishers Ltd. in Current Pharmacogenomics and Personalized Medicine
- Vol. 21 (3) , 155-164
Understanding Bacterial Roles in Cancer Chemo-resistance: A Signaling Pathway Mapping Study
Introduction: Chemoresistance is one of the leading causes of chemotherapy failure among cancer patients. Out of several hypotheses proposed for chemoresistance, bacteria-mediated chemoresistance to cancer drugs has not been well established. Thus, the aim of this review is to map the pathways by which bacteria exhibit chemoresistance in specific cancers. Material and Methods: Relevant articles on bacteria-mediated chemoresistance in cancer were retrieved by conducting a systematic search across PubMed, Scopus and Web of Science databases. The search was limited to English original articles published until 15th December 2023. Results: A total of nine articles were included to map the pathways involved in chemoresistance. Numerous pathways have been connected to various forms of cancer, such as autophagy pathway in colorectal and esophageal cancers by Fusobacterium nucleatum causing oxaliplatin and 5-FU resistance; DNA damage response pathway also by Fusobacterium nucleatum promoting CDDP resistance in esophageal cancer; Porphyromonas gingivalis led to oral and esophageal cancer resistance to paclitaxel via JAK/STAT pathway. NF-κB pathway involved in gastric cancer in the presence of Helicobacter pylori towards cisplatin, and also 5-FU resistance via the apoptotic pathway. Cellular metabolism modulation by Lactobacillus iners was also implicated in cervical cancer chemoresistance. Conclusion: We conclude that bacteria can mediate chemoresistance not merely to antibiotics but also to anticancer drugs. Thus, a detailed understanding of the pathways associated with chemoresistance mediated via bacteria might help in targeting these pathways or antibiotics to prevent bacterial growth could help overcome resistance.
- 3 August 2024
- Published by Springer Nature in Indian Journal of Otolaryngology and Head & Neck Surgery
- Vol. 76 (6) , 5154-5169
Association of Unsafe Sexual Behavior with Head and Neck Cancer: A Bibliometric Analysis
Inappropriate sexual practice like oral sex has been linked with head and neck cancer (HNC). The recent data revealed that about 20% oropharyngeal caner among Indians are associated with oral sex. Thus, we aimed to comprehensively assess the trend of research in oral sex associated with HNC and to predict the research frontiers and potential hotspots in the near future. The publications related to oral sex and HNC were retrieved from Scopus database via systematic search strategy (till 15th July 2023). VOSviewer version 1.6.19 and Biblioshiny software were used to identify the trends and research hotspots. A total of 2,179 original articles has been identified of which United States had the highest number of articles (837) followed by United Kingdom (155) and India (140). The number of articles in the area of oral sex and HNC has been increased significantly over decades (highest in 2022: 169 articles) which suggests the trend of the research. Most of the studies were from the National Cancer Institute and most of the studies were published in oral oncology journal (76) along with the 3231 citations. HNC, Human papilloma virus (HPV), oropharyngeal cancer and oral cancer are the enriched keywords which suggests that the individual practicing oral sex are prone to HPV infection which results into HNC. HPV infection mediated via oral sex might be the reason behind the surge of HNC which needs to be addressed via spreading awareness, proper counseling and integrating sex education in study curriculum.
- 3 August 2024
- Published by Springer Nature in Indian Journal of Otolaryngology and Head & Neck Surgery
- Vol. 76 (6) , 5154-5169
Association of Unsafe Sexual Behavior with Head and Neck Cancer: A Bibliometric Analysis
Inappropriate sexual practice like oral sex has been linked with head and neck cancer (HNC). The recent data revealed that about 20% oropharyngeal caner among Indians are associated with oral sex. Thus, we aimed to comprehensively assess the trend of research in oral sex associated with HNC and to predict the research frontiers and potential hotspots in the near future. The publications related to oral sex and HNC were retrieved from Scopus database via systematic search strategy (till 15th July 2023). VOSviewer version 1.6.19 and Biblioshiny software were used to identify the trends and research hotspots. A total of 2,179 original articles has been identified of which United States had the highest number of articles (837) followed by United Kingdom (155) and India (140). The number of articles in the area of oral sex and HNC has been increased significantly over decades (highest in 2022: 169 articles) which suggests the trend of the research. Most of the studies were from the National Cancer Institute and most of the studies were published in oral oncology journal (76) along with the 3231 citations. HNC, Human papilloma virus (HPV), oropharyngeal cancer and oral cancer are the enriched keywords which suggests that the individual practicing oral sex are prone to HPV infection which results into HNC. HPV infection mediated via oral sex might be the reason behind the surge of HNC which needs to be addressed via spreading awareness, proper counseling and integrating sex education in study curriculum.
- 23 July 2024
- Published by Elsevier in Clinical Nutrition ESPEN
- Vol. 63, 564-571
Assessment of taste alteration and its correlation with nutritional status and quality of life among cancer patients undergoing chemotherapy
- 23 July 2024
- Published by Elsevier in Clinical Nutrition ESPEN
- Vol. 63, 564-571
Assessment of taste alteration and its correlation with nutritional status and quality of life among cancer patients undergoing chemotherapy
- 10 May 2024
- Published by Elsevier in Gene Reports
- Vol. 36
Decoding the role of SPRR1A and SPRR1B gene in cancer: A comprehensive review
- 10 May 2024
- Published by Elsevier in Gene Reports
- Vol. 36
Decoding the role of SPRR1A and SPRR1B gene in cancer: A comprehensive review
- 17 April 2024
- Published by Elsevier in Indian Journal of Tuberculosis
- Vol. 72 (3) , 290-297
Healthcare schemes to overcome financial toxicity of COVID-19: A retrospective single center study
- 17 April 2024
- Published by Elsevier in Indian Journal of Tuberculosis
- Vol. 72 (3) , 290-297
Healthcare schemes to overcome financial toxicity of COVID-19: A retrospective single center study
- 7 August 2023
- Published by Taylor & Francis
- p. 167-177
Corn Silk (Stigma maydis) Use in Diabetes
Isolated compounds and extracts from various medicinal plants were studied for their potential use in diabetes therapy. Corn is also known as maize, and its seeds are edible in most Asian countries. Corn silk is a long, pigmented (yellowish to reddish) hair-like structure covering the edible portion of corn. This review focuses on the molecular, cellular, and metabolic effects of corn silk (Stigma maydis) in the treatment of diabetes. The antidiabetic effect of corn silk is due to the potential candidates such as the presence of flavonoids, phenolic acids, phytosterols, carotenoids, and tannins. We discuss the effect of corn silk on cellular and molecular pathways involved in preventing and treating diabetes. Further, we cover corn silk’s toxicity and summarize other plants or parts used in diabetes treatment.
- 7 August 2023
- Published by Taylor & Francis
- p. 167-177
Corn Silk (Stigma maydis) Use in Diabetes
Isolated compounds and extracts from various medicinal plants were studied for their potential use in diabetes therapy. Corn is also known as maize, and its seeds are edible in most Asian countries. Corn silk is a long, pigmented (yellowish to reddish) hair-like structure covering the edible portion of corn. This review focuses on the molecular, cellular, and metabolic effects of corn silk (Stigma maydis) in the treatment of diabetes. The antidiabetic effect of corn silk is due to the potential candidates such as the presence of flavonoids, phenolic acids, phytosterols, carotenoids, and tannins. We discuss the effect of corn silk on cellular and molecular pathways involved in preventing and treating diabetes. Further, we cover corn silk’s toxicity and summarize other plants or parts used in diabetes treatment.